Double Stimulation (Elonva+rFSH) in luteal /follicular phase + Conventional Stimulation (Elonva+rFSH) in follicular phase
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Infertility
Conditions
Infertility
Trial Timeline
Oct 30, 2020 → May 2, 2023
NCT ID
NCT04446845About Double Stimulation (Elonva+rFSH) in luteal /follicular phase + Conventional Stimulation (Elonva+rFSH) in follicular phase
Double Stimulation (Elonva+rFSH) in luteal /follicular phase + Conventional Stimulation (Elonva+rFSH) in follicular phase is a approved stage product being developed by Merck for Infertility. The current trial status is completed. This product is registered under clinical trial identifier NCT04446845. Target conditions include Infertility.
What happened to similar drugs?
10 of 20 similar drugs in Infertility were approved
Approved (10) Terminated (4) Active (10)
🔄GenSci094 + Placebo RecFSH / follitropin alfa + Biological: RecFSH / Follitropin alfa (Days 1 to 7) + Placebo GenSci094 + RecFSH / Follitropin alfa (Days 8 to hCG) + Ganirelix + hCG + ProgesteroneSun PharmaceuticalPhase 3
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04446845 | Approved | Completed |
Competing Products
20 competing products in Infertility